TIGIT Remains a Tempting Target for Immunotherapy Combinations, Despite Setbacks OncLive, 13 Apr 2023 Jedd D. Wolchok, MD, PhD, FASCO Despite a high-profile clinical disappointment, the TIGIT immune checkpoint remains an…